The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK

Rheumatology

Volumn 46, Issue 8, 2007, Pages 1338-1344

  Ara, R M ^a   Reynolds, A V ^b   Conway, P ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Ankylosing spondylitis; Cost effectiveness; Cost utility; Economic evaluation; Health status; Tumour necrosis factor

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG RESPONSE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MONOTHERAPY; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; UNITED KINGDOM;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; IMMUNOGLOBULIN G; MALE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; STATE MEDICINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547851825     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem133     Document Type: Article

References (38)

1. Zochling J, van der Heijde D, Burgos-Vargas R et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
2. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. German Collaborative Arthritis Contras. J Rheumatol 2000;27:613-22.
3. Ward M. Health-related quality of life in ankylosing spondylitis: A survey of 175 patients. Arthritis Care Res. 1999;12:247-55.
4. Barkham N, Kong KO, Tennant A et al. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology 2005;44:1277-81.
5. Davis JC, van der Heijde D, Dougados M, Woolley JM. Reductions in healthrelated quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005;53:494-501.
6. Boonen A, de Vet H, van der Heijde D, van der Linden S. Work status and its determinants among patients with ankylosing spondylitis. A systematic review of the literature. J Rheumatol 2001;28:1056-62.
7. Barlow JH, Wright CC, Williams B, Keat A. Work disability among people with ankylosing spondylitis. Arthritis Rheum 2001;45:424-9.
8. Ward M. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
9. Boonen A, van der Heijde D, Landewe R et al. Work status and productivity costs due to ankylosing spondylitis: Comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
10. Kest A, Barkham N, Bhalla A et al. BSR Guidelines for prescribing TNF alpha Blockers in Adults with Ankylosing Spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology 2005;44:939-47.
11. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis; a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
12. Braun J, Pham T, Sieper J et al. ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
13. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
14. Kobelt G, Andlin-Sobocki P, Brophy S et al. The burden of ankylosing spondylitis and the cost-efectiveness of treatment with infliximab (Remicade®). Rheumatology 2004;43:1158-66.
15. Kobelt G, Andlin-Sobocki P, Maksyrnowych WP. Costs and Quality of Life of Patients with Ankylosing Spondylitis in Canada. J Rheumatol 2006;33:289-95.
16. Boonen A, van der Heijda D, Severens J, Boemdermaker A, Landewe R. Markov model into the cost-utility over 5 years of etanercept and infliximab compared to usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 2005; doi:20.1136/ard.2004.032565.
17. National Institute for Clinical Excellence. Health Technology Appraisal. Adalimumab, etanercept and infliximab for ankylosing spondylitis. Final Scope. Available at http://www.nice.org.uk/page.aspx?o=273674.
18. Guide to the Methods of Technology Appriasal. London. NICE 2004 NO515
19. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in anklysosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;1:2286-91.
20. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
21. Van der Heijde D, Da Silva J, Dougados M et al. Once-weeldy 50-mg dosing of etanercept is as effective as twice-weekly dosing in patients withankylosing spondylitis. Abstract EULAR [SAT0195], 2006.
22. Davis JC, van der Heijde D, Braun D et al. Recombinant tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum 2003;48:3230-6.
23. Davis JC, van der Heijde D, Braun J. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557-62.
24. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. Reference N0515, 2004. http://www.nice.org.uk/pdf/ TAP_Methods.pdf.
25. Sieper J, Dijkmans BAC, Van der Linden S, Martin Mola E. Long term efficacy and safety of etanercept in patients with ankylosing spondylitis: 148 to 160 week analysis from an ongoing trial. Abstract EULAR [FRI0508], 2006.
26. Ara RM, Peckham J, Haywood K. The direct healthcare resource costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit. Abstract EULAR [THU0523-AHP], 2006.
27. Tahir H, Moore S, Ehrenstein MR. Comparison of Anti-TNF therapy in daily practice. Poster Abstract, BSR, 2005.
28. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice. Results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;4:600-6.
29. Robertson LP, Davis MJ. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis. Rheumatology 2004;43:1565-8.
30. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993;52:174-6.
31. Simmonds DPM. Mortality in ankylosing spondylitis. Rheum Europe 1996;4:15-6.
32. http://www.bnf.org.uk/bnf/
33. http://www.pssru.ac.uk/
34. http://www.dh.gov.uk/
35. Brennan A, Bansback NJ, Reynolds A, Conway P. Modelling the costeffectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004;43:62-72.
36. Bansback NJ, Ara R, Barkham N et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.. Rheumatology 2006;45(8):1029-38.
37. Weinblat ME, Genovese MC, Moreland LW et al. Efficacy and Safety of Over 9 Years of Etanercept (Enbrel®) Therapy in North American Patients with Early and Long-Standing Rheumatoid Arthritis. ACR 2006, Abstract 510.
38. Klareskog, Gaubitz: M, Rodriguez-Valverde V et al. The Etanercept Study 301 Investigators. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease modifying antirheumatic drugs. Ann Rheum Dis 2006;65:1578-84.